Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine (NBIX) to $164 from $160 and keeps a Buy rating on the shares. The firm said he quarter was solid again, and Ingrezza (valbenazine for tardive dyskinesia/TD, Huntington’s chorea) sales came in at $687mn vs. our $650mn and FactSet consensus of $668mn. Canaccord continues to view commercial execution over the next several quarters as a very important variable for the stock to continue to work as the Street prepares for Phase 3 datasets on osavampator for MDD in 2027E, and direclidine (M4 agonist) for schizophrenia in 2027/28E.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $203 from $175 at Citi
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth
- Neurocrine’s Strong Q3 Performance and Growth Potential Justify Buy Rating
- Neurocrine’s Strong Performance and Strategic Initiatives Drive Buy Rating